Sevelamer HydrochlorideA Review of its Use for Hyperphosphataemia in Patients with End-Stage Renal Disease on Haemodialysis

被引:0
作者
David R. Goldsmith
Lesley J. Scott
Risto S. Cvetković
Greg L. Plosker
机构
[1] Wolters Kluwer Health ¦ Adis,
[2] Wolters Kluwer Health,undefined
来源
Drugs | 2008年 / 68卷
关键词
Coronary Artery Calcification Score; Phosphate Binder; Sevelamer; Lanthanum Carbonate; Serum Phosphorus Level;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:85 / 104
页数:19
相关论文
共 123 条
[1]  
Bailie GR(2004)Calcium and phosphorus management in chronic kidney disease: challenges and trends Formulary 39 358-65
[2]  
Hutchison AJ(2004)Improving phosphate-binder therapy as a way forward Nephrol Dial Transplant 19 i19-24
[3]  
Qunibi WY(2004)Consequences of hyperphosphatemia in patients with end-stage renal disease (ESRD) Kidney Int Suppl 66 S8-12
[4]  
Block GA(2004)Mineral metabolism, mortality, and morbidity in maintenance hemodialysis J Am Soc Nephrol 15 2208-18
[5]  
Klassen PS(2005)Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study Kidney Int 67 1179-87
[6]  
Lazarus JM(2003)K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease Am J Kidney Dis 42 S1-201
[7]  
Young EW(2004)A comparison of clinically useful phosphorus binders for patients with chronic kidney failure Kidney Int Suppl 66 S25-32
[8]  
Albert JM(2004)Vascular calcification: a stiff challenge for the nephrologist: does preventing bone disease cause arterial disease? Kidney Int 66 1315-33
[9]  
Satayathum S(2004)Factors for increased morbidity and mortality in uremia: hyperphosphatemia Semin Nephrol 24 396-400
[10]  
Emmett M(2004)The role of sevelamer in achieving the kidney disease outcomes quality initiative (K/ DOQI) guidelines for hyperphosphatemia Curr Med Res Opin 20 991-9